BioCorRx Inc.

Equities

BICX

US09073C2052

Healthcare Facilities & Services

Market Closed - OTC Markets 11:36:28 2024-04-26 am EDT 5-day change 1st Jan Change
0.75 USD -8.54% Intraday chart for BioCorRx Inc. -48.98% -3.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioCorRx Inc. Announces Board Resignations CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors CI
BioCorRx Inc. Announces President Changes CI
BioCorRx Inc. announced that it has received $0.2 million in funding CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioCorRx Inc. announced that it has received $0.2 million in funding CI
Biocorrx Inc. Announces Management Changes CI
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Insider Buy: Biocorrx MT
BioCorRx Inc. announced that it has received $0.299983 million in funding CI
BioCorRx Inc. announced that it has received $0.599536 million in funding CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BioCorRx Inc. Auditor Raises 'Going Concern' Doubt CI
BioCorRx Inc. announced that it expects to receive $0.599536 million in funding CI
BioCorRx Inc. Announces Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial At 4Th Annual NIH HEAL Initiative Investigator Meeting CI
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors CI
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc CI
BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States CI
BioCorRx Inc. agreed to Spin-Off BioCorRx Pharmaceuticals, Inc. CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104 CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart BioCorRx Inc.
More charts
BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
More about the company

Annual profits - Rate of surprise